Presentation on Innovative approached to Treat Diabetes by Dr. Oren Fuerst of LabStyle (Ticker Symbol DRIO) at the Israeli Medical Devices International Conference Haifa October 8 2013
Upcoming SlideShare
Loading in...5
×
 

Presentation on Innovative approached to Treat Diabetes by Dr. Oren Fuerst of LabStyle (Ticker Symbol DRIO) at the Israeli Medical Devices International Conference Haifa October 8 2013

on

  • 496 views

Cloud based technologies and Mobile devices can dramatically alter the way we handle chronic illness. Dario is an innovative approach to tackle diabetes by offering a wealth of services and products ...

Cloud based technologies and Mobile devices can dramatically alter the way we handle chronic illness. Dario is an innovative approach to tackle diabetes by offering a wealth of services and products driven by personalized software. combination of machine learning tools alters the mindset of diabetes treatment in a most fundamental way by tweaking each and every step of the value chain of the diabetes landscape.

Statistics

Views

Total Views
496
Views on SlideShare
496
Embed Views
0

Actions

Likes
0
Downloads
182
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Presentation on Innovative approached to Treat Diabetes by Dr. Oren Fuerst of LabStyle (Ticker Symbol DRIO) at the Israeli Medical Devices International Conference Haifa October 8 2013 Presentation on Innovative approached to Treat Diabetes by Dr. Oren Fuerst of LabStyle (Ticker Symbol DRIO) at the Israeli Medical Devices International Conference Haifa October 8 2013 Presentation Transcript

  • The Perspective of LabStyle Innovations Corp. (DRIO: US Over the Counter)- Innovative Solutions for Diabetics in a Mobile Age Presentation- October 8 Haifa Dr. Oren Fuerst, Executive Chairman Dario Wednesday, October 9, 13
  • Disclaimer Regarding Forward-Looking Statements   This presentation of LabStyle Innovations Corp. (the “Company”) and statements of the Company’s management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").  Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions all denote forward-looking statements within the meaning of the Act.  Factors that could cause or contribute to such differences include the Company’s compliance with regulatory requirements, the Company’s status as a new public company, the impact of current and any future competition, as well as other factors and risks discussed in the Company's filings with the U.S. Securities and Exchange Commission.   Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements.The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.   In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by Company management or its agents have been prepared by Company management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to the future performance of the Company. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles. Wednesday, October 9, 13
  • Wednesday, October 9, 13
  • 2013 2022 $12b $27b (Up 170%) 400mdiabetics 20-30%insulin dependent 80-120mPrimary initial target users Global glucose self-monitoring market (primarily test strips) Large and Growing Global Market Wednesday, October 9, 13
  • 2011 2018 $37b $72b 2011 2030 10% CAGR 370m 550m Source:Transparency Market Research, "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario,Trends,Analysis, Size, Share and Forecast, 2011 - 2018," Global Diabetes (therapeutics devices and drugs) market Number of Diabetics Worldwide Diabetes:A Large and Growing Market Wednesday, October 9, 13
  • Creating the ‘Artificial Diabetes Brain’, as a springboard of services and products leading to healthier and better life of diabetics worldwide. Dario Value Proposition Wednesday, October 9, 13
  • Creating the ‘Artificial Diabetes Brain’, as a springboard of services and products leading to healthier and better life of diabetics worldwide. Dario Value Proposition Strips Wednesday, October 9, 13
  • Insulin Creating the ‘Artificial Diabetes Brain’, as a springboard of services and products leading to healthier and better life of diabetics worldwide. Dario Value Proposition Strips Wednesday, October 9, 13
  • Diabetes Complications Insulin Creating the ‘Artificial Diabetes Brain’, as a springboard of services and products leading to healthier and better life of diabetics worldwide. Dario Value Proposition Strips Wednesday, October 9, 13
  • Diabetes Complications Insulin Creating the ‘Artificial Diabetes Brain’, as a springboard of services and products leading to healthier and better life of diabetics worldwide. Dario Value Proposition Strips Wednesday, October 9, 13
  • Dario:“Artificial Diabetes Brain”, All-in-one mobile and cloud based diabetes management system with glucose measurement device, data capture and analytics, sharing and social features -Concluded usability and accuracy studies -Obtained CE Mark for Europe. UK, Belgium, Italy distribution agreements - Software launch on European Appstore Q4 - 510(k) path for the USA -Reimbursable, recurring, test strips revenue based model -Expanding into a hub of solutions for Diabetics (e.g. revenue from integration with smart insulin pens; clinical studies; product market testing) -More than 400M diabetics worldwide (close to 100M are insulin dependent). -$12bn test strips market and growing ($37bn overall diabetes market) -Very little real innovation ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ LabStyle Innovations InvestmentTheme Wednesday, October 9, 13
  • Enter Dario www.mydario.com Wednesday, October 9, 13
  • Enter Dario www.mydario.com Wednesday, October 9, 13
  • Wednesday, October 9, 13
  • Social Network - Crowd Source Multi Mobile Platform - Cloud Service Monitoring Dario Software Easy to use, Stylish,All in One Monitoring Device Actionable Personalized Insights Improve Diabetic Health - Monitoring toTherapy Dario End to End Lifecycle Therapy Insulin (Pens; pumps), Diabetic Food, Exercise, Behavior Wednesday, October 9, 13
  • 1990s 2000s Glucose Self-Monitoring Devices Have changed much over the past years Wednesday, October 9, 13
  • http://chocolateonmycranium.blogspot.com/2011/05/changes.html#.T8Yc05kthbo Device Lancer Strips A bulky Kit Cumbersome to Carry Wednesday, October 9, 13
  • Phone + meter Meter + lancer Current Attempts Combine Hardware - Rather than providing an E2E Customer Experience Wednesday, October 9, 13
  • Data is Lost Wednesday, October 9, 13
  • Smartphone-driven Glucose Meter Lancing device and strip container Patent-pending technology Dario The Device Pocket Size Glucose Meter Stylish and easy to use Wednesday, October 9, 13
  • Community Based - Learn and Share Data Analysis and Insights Proactive Recommendation Based on Pattern Recognition EndTo End Diabetes Lifestyle Management (Food, Exercise, Insulin Intake) ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ Comprehensive Platform - Patient, Care Giver, Professional Healthcare ‫


  • נגטיב‬‫ו‬‫לוג‬ Dario The Software Goals and Objectives via Gamification ‫


  • נגטיב‬‫ו‬‫לוג‬ Wednesday, October 9, 13
  • Dario The App Wednesday, October 9, 13
  • Physician Dietitian Nurse Other care givers Patient REAL-TIME DATA HISTORICAL DATA TAILOR-MADE DATA ANALYZED DATA Dramatically improving information flow among patients and care givers Wednesday, October 9, 13
  • Physician Dietitian Nurse Other care givers Patient Big Data and Proactive Care at its best REAL-TIME DATA HISTORICAL DATA TAILOR-MADE DATA ANALYZED DATA •Pattern Recognition to yield personalization of Insulin Regimen •New regimen tested in real time •Real-Time clinical and marketing studies potential (Recruitment; Data capture;Analysis) •Prediction of Diabetes complications and the need for immediate actions Wednesday, October 9, 13
  • Combining direct to consumers and distributors model Test strips are typically fully reimbursed;Alignment with HC Insurance Agenda Data enables a natural expansion into insulin delivery (e.g. smart insulin pen) Initially: Recurring, high margin revenue from sales of strips ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ Platform enables revenue from clinical studies and data (e.g. pharma; food) User base enables product partnerships (e.g. pharma; food) ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ Revenue Model Highlights ‫


  • נגטיב‬‫ו‬‫לוג‬ Illustration: 5 Strips/day*$0.5/Strip*365days/year*100,000 clients>$90M/year Wednesday, October 9, 13
  • Wednesday, October 9, 13
  • Wednesday, October 9, 13
  • Wednesday, October 9, 13
  • Dario:“Artificial Diabetes Brain”,All-in-one mobile and cloud based diabetes management system with glucose measurement device, data capture and analytics, sharing and social features -Concluded usability and accuracy studies -Obtained CE Mark for Europe. UK, Belgium, Italy distribution agreements - Software launch on European Appstore Q4 - 510(k) path for the USA -Reimbursable, recurring, test strips revenue based model -Expanding into a hub of solutions for Diabetics (e.g. revenue from integration with smart insulin pens; clinical studies; product market testing) -More than 400M diabetics worldwide (close to 100M are insulin dependent). -$12bn test strips market and growing ($37bn overall diabetes market) -Very little real innovation ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ LabStyle Innovations- Dario Summary Wednesday, October 9, 13
  • Dario ThankYou! Wednesday, October 9, 13
  • Wednesday, October 9, 13
  • Oren Fuerst, PhD Executive Chairman Erez Raphael CEO & President Tal Givoly CTO Seasoned medtech entrepreneur and investor Former facultyYale and Columbia Business School Extensive experience in medical devices and data mgt Former Chief Scientist of Amdocs (NYSE:DOX) More than 25 years in software development Software inventor with more 25+ granted patents Prof. Itamar Raz MD Head of SAB Head of Diabetes Unit and Research Center, Hadassah Medical Center; Israel National Council of Diabetes of the Israel Ministry of Health; President, Israel Diabetes Research Group. 20 years of experience in product design, development and commercialization. Formerly with Amdocs (NYSE: DOX) and Nokia-Siemens Shosh Friedman VP Clinical and Regulatory Affairs Former SVP Clinical and Regulatory Affairs at Given Imaging (NASDAQ:GIVN). More than 20 years in clinical, regulatory affairs and QA systems. Experienced ManagementTeam Wednesday, October 9, 13
  • Oren Fuerst, PhD Co-Founder Malcolm Hoenlein Prof. Nahum Melumad PhD Adam Stern Seasoned entrepreneur and investor Founder ofTevel Global & Strategic Models Former faculty Columbia Business School. Extensive experience in medical devices and data management CEO, ExecutiveVice-Chairman, Conference of Major American Jewish Organizations Director, Council of Foreign Relations Professor of Accounting and Business Law, Columbia Business School Consultant to J&J, Bristol-Myers, GE Head of Private Equity Banking at Aegis Capital and CEO of SternAegisVentures Director inVivo, Organovo, Prolor 20+ years of investment experience David Weintraub MD Co-Founder Co-founder, Medical Director Ramat-Aviv MC Serial entrepreneur and inventor Founder ofVersamed (acquired by GE) Itamar Raz MD Head of Diabetes Unit, Hadassah Medical Center Head, Israel National Council of Diabetes President, Israel Diabetes Research Group Board of directors Wednesday, October 9, 13
  • Delaware Company Founded 2011, based on IP from 2010 Share Price $2.79. Market Cap $55M Shares Outstanding 19.284M (Float ~ 11.5M shares) Public Since March 2013 (Through S1) Raised $16M, including $10M in May 2013 Developer of Dario, an all-in-one mobile and cloud based diabetes management system with glucose measurement device, data capture and analytics, sharing and social features enabling proactive care ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ ‫


  • נגטיב‬‫ו‬‫לוג‬ LabStyle Innovations (DRIO:OTCBB) Corporate Snapshot Wednesday, October 9, 13